These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 34742130)

  • 21. Predictive immunogenetic markers in COVID-19.
    Leite MM; Gonzalez-Galarza FF; Silva BCCD; Middleton D; Santos EJMD
    Hum Immunol; 2021 Apr; 82(4):247-254. PubMed ID: 33546902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cytokine storm-An appropriate, over-reactive response to SARS-CoV-2 or the wrong immune pathway?
    Bellgrau D; Modiano JF
    Scand J Immunol; 2021 Mar; 93(3):e12979. PubMed ID: 32991014
    [No Abstract]   [Full Text] [Related]  

  • 23. Brief annotations on cytokine release syndrome and interleukin-6 therapeutic blockage in SARS-CoV-2/COVID-19.
    Amezcua-Guerra LM
    Arch Cardiol Mex; 2020; 90(Supl):84-87. PubMed ID: 32523147
    [No Abstract]   [Full Text] [Related]  

  • 24. Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword.
    Tan LY; Komarasamy TV; Rmt Balasubramaniam V
    Front Immunol; 2021; 12():742941. PubMed ID: 34659238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?
    Morris G; Bortolasci CC; Puri BK; Marx W; O'Neil A; Athan E; Walder K; Berk M; Olive L; Carvalho AF; Maes M
    Cytokine; 2021 Aug; 144():155593. PubMed ID: 34074585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absent immune response to SARS-CoV-2 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case.
    Gao G; Zhu Z; Fan L; Ye S; Huang Z; Shi Q; Sun Y; Song Q
    Infection; 2021 Feb; 49(1):57-61. PubMed ID: 32725596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.
    Shcherbak SG; Anisenkova AY; Mosenko SV; Glotov OS; Chernov AN; Apalko SV; Urazov SP; Garbuzov EY; Khobotnikov DN; Klitsenko OA; Minina EM; Asaulenko ZP
    Front Immunol; 2021; 12():745515. PubMed ID: 34858403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective.
    Perazzolo S; Zhu L; Lin W; Nguyen A; Ho RJY
    J Pharm Sci; 2021 Mar; 110(3):1002-1017. PubMed ID: 33248057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Involvement of the complement cascade in severe forms of COVID-19].
    Chouaki Benmansour N; Carvelli J; Vivier É
    Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.
    Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P
    Front Immunol; 2021; 12():589095. PubMed ID: 33995341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of the inflammatory response and megakaryocytes in COVID-19 infection.
    Battina HL; Alentado VJ; Srour EF; Moliterno AR; Kacena MA
    Exp Hematol; 2021 Dec; 104():32-39. PubMed ID: 34563606
    [No Abstract]   [Full Text] [Related]  

  • 32.
    Khan FI; Hassan F; Lai D
    Front Immunol; 2021; 12():794780. PubMed ID: 35095870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
    Khaedir Y; Kartika R
    J Interferon Cytokine Res; 2021 Feb; 41(2):37-43. PubMed ID: 33621130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What triggers severe COVID? Infected immune cells hold clues.
    Mallapaty S
    Nature; 2022 Apr; 604(7905):231. PubMed ID: 35388153
    [No Abstract]   [Full Text] [Related]  

  • 36. Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!
    Coperchini F; Chiovato L; Rotondi M
    Front Immunol; 2021; 12():668507. PubMed ID: 33981314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach.
    Obando-Pereda G
    J Med Virol; 2021 Sep; 93(9):5350-5357. PubMed ID: 33913542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monocytes and Macrophages in COVID-19.
    Knoll R; Schultze JL; Schulte-Schrepping J
    Front Immunol; 2021; 12():720109. PubMed ID: 34367190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
    Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
    Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.